Details of the Drug Combinations

General Information of This Drug (ID: DMSCR2H)

Drug Name

Cerdulatinib DMSCR2H

Synonyms

PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
B-cell lymphoma	2A86	Phase 2	[1]
Non-hodgkin lymphoma	2B33.5	Phase 1/2	[2]
Atopic dermatitis	EA80	Phase 1	[3]
Vitiligo	ED63.0	Phase 1	[3]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cerdulatinib + Panobinostat	DC7L6XT	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of Portola.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.